Helus Pharma Raises $50M in Underwritten Share Offering
Event summary
- Helus Pharma priced an underwritten offering of 10,309,280 common shares at $4.85 per share, raising $50 million in gross proceeds.
- The offering is expected to close on June 25, 2026, subject to regulatory approvals from Cboe Canada and Nasdaq.
- Proceeds will fund Phase 3 trials for HLP003 (major depressive disorder), development of HLP004 (generalized anxiety disorder), and general corporate purposes.
The big picture
Helus Pharma's $50 million raise underscores investor confidence in its novel serotonergic agonists pipeline, particularly as mental health treatments gain urgency. The funding comes amid a wave of biotech financings targeting neuroplasticity pathways, with Helus positioning itself as a leader in adjunctive therapies for depression and anxiety. Success hinges on delivering Phase 3 data that meets or exceeds expectations.
What we're watching
- Clinical Milestones
- Whether Phase 3 data for HLP003 in Q4 2026 will validate its Breakthrough Therapy Designation and accelerate regulatory approval.
- Capital Deployment
- How effectively Helus Pharma allocates the $50 million across its pipeline, particularly for HLP004 and HLP005 programs.
- Market Positioning
- The pace at which Helus Pharma can differentiate itself in the competitive serotonergic agonists space.
Related topics